Avidity Biosciences, Inc. will host an investor and analyst event to discuss initial data from the EXPLORE44 trial of delpacibart zotadirsen in people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping.
AI Assistant
AVIDITY BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.